| 货号 | 规格 | 价格 | 上海 | 北京 | 珠海 | 重庆 | 武汉 | 购买数量 |
|---|---|---|---|---|---|---|---|---|
S81127-1mg买3赠1 |
99.40% | ￥200.00 |
>10 | - | - | - | - |
|
S81127-5mg买3赠1 |
99.40% | ￥350.00 |
>10 | - | - | - | - |
|
S81127-10mg买3赠1 |
99.40% | ￥600.00 |
>10 | - | - | - | - |
|
S81127-25mg买3赠1 |
99.40% | ￥1000.00 |
>10 | - | - | - | - |
|
S81127-50mg买3赠1 |
99.40% | ￥1800.00 |
>10 | - | - | - | - |
|
S81127-100mg买3赠1 |
99.40% | ￥3200.00 |
>10 | - | - | - | - |
|
| 产品描述： | Sacubitril/Valsartan (LCZ696), comprised Valsartan and Sacubitril (AHU377) in 1:1 molar ratio, is a first-in-class, orally bioavailable, and dual-acting angiotensin receptor-neprilysin (ARN) inhibitor for hypertension and heart failure. Sacubitril/Valsartan ameliorates diabetic cardiomyopathy by inhibiting inflammation, oxidative stress and apoptosis | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 靶点： | Angiotensin receptor-neprilysin;Apoptosis; RAAS; Neprilysin | ||||||||||||||||||||
| 体外研究： | Sacubitril/Valsartan (LCZ696; 1-30 µM; 0.5 hours) inhibits HG-treated H9C2 cells apoptosis in an experimental model of Diabetic cardiomyopathy (DCM). Sacubitril/Valsartan (1-30 µM; 0.5 hours) increases the expression level of cleaved caspase-3 and the ratio of Bax/Bcl-2 in HG-treated H9C2 cells. Apoptosis Analysis Cell Line: HG-treated H9C2 cells Concentration: 1, 10, or 30 µM Incubation Time: 0.5 hours Result: Inhibited HG-treated H9C2 cells apoptosis. Western Blot Analysis Cell Line: HG-treated H9C2 cells Concentration: 1, 10, or 30 µM Incubation Time: 0.5 hours Result: Increased the expression level of cleaved caspase-3 and the ratio of Bax/Bcl-2. | ||||||||||||||||||||
| 体内研究： | Sacubitril/Valsartan (LCZ696; perorally; 68 mg/kg for 4 weeks) significantly exhibits small weights and reduces interstitial fibrosis both in the noninfarct zone and peri-infarct zone. Animal Model: Adult 6- to 8-week-old male Sprague-Dawley rats (220-250 g body weight) Dosage: 68 mg/kg Administration: Perorally; for 4 weeks Result: Exhibited small weights and reduced interstitial fibrosis both in the noninfarct zone and peri-infarct zone. | ||||||||||||||||||||
| 参考文献： | 1. Gu J, et al. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). J Clin Pharmacol. 2010 Apr;50(4):401-14. 2. von Lueder TG, et al. Angiotensin receptor neprilysin inhibitor LCZ696 attenuates cardiac remodeling and dysfunction after myocardial infarction by reducing cardiac fibrosis and hypertrophy. Circ Heart Fail. 2015 Jan;8(1):71-8. 3. Huo H, et al. Erastin Disrupts Mitochondrial Permeability Transition Pore (mPTP) and Induces Apoptotic Death of Colorectal Cancer Cells. PLoS One. 2016 May 12;11(5):e0154605. 4. Ge Q, et al. Feature article: LCZ696, an angiotensin receptor-neprilysin inhibitor, ameliorates diabeticcardiomyopathy by inhibiting inflammation, oxidative stress and apoptosis. Exp Biol Med (Maywood). 2019 Sep;244(12):1028-1039. | ||||||||||||||||||||
| 溶解性： | Soluble in DMSO、H2O | ||||||||||||||||||||
| 保存条件： | -20℃ | ||||||||||||||||||||
| 配置溶液浓度参考： |
|
||||||||||||||||||||
| 注意： | 部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，仅供客户参考交流研究之用。 |
上海工商
沪公网安备 31011702002021号
危险品化学品经营许可证（不带存储）
营业执照(三证合一)
北京